We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+19.81%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.35B
AUM Growth
+$99.6M
Cap. Flow
-$51.8M
Cap. Flow %
-3.83%
Top 10 Hldgs %
51.22%
Holding
199
New
40
Increased
30
Reduced
31
Closed
45

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$43.2M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$19.8M
3
BAX icon
Baxter International
BAX
+$15.5M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$13.3M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$11.5M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$22.7M
2
RLYP
RELYPSA INC COM
RLYP
+$18.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$17.6M
4
CEMP
Cempra, Inc.
CEMP
+$16.2M
5
SHPG
Shire pic
SHPG
+$8.41M

Sector Composition

Rank Sector Weight
1 Healthcare 86%
2 Consumer Discretionary 0.08%
3 Financials 0.04%
4 Consumer Staples 0.02%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYNE
51
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$5.62M 0.42%
558,446
-20,904
-4% -$277K
NERV icon
52
Minerva Neurosciences
NERV
$191M
$4.92M 0.36%
101,317
– –
ANTH
53
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$4.6M 0.34%
124,020
– –
NDRM
54
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$4.6M 0.34%
270,000
– –
TARA icon
55
Protara Therapeutics
TARA
$214M
$4.26M 0.32%
6,875
– –
ASXC
56
DELISTED
Asensus Surgical, Inc.
ASXC
$4.26M 0.31%
131,995
-8,500
-6% -$274K
ELDN icon
57
Eledon Pharmaceuticals
ELDN
$255M
$4.23M 0.31%
2,996
– –
ADYX
58
DELISTED
Adynxx Inc
ADYX
$4.11M 0.3%
32,033
– –
SPNC
59
DELISTED
Spectranetics Corp
SPNC
$4.06M 0.3%
+269,570
New +$3.56M
SRPT icon
60
PUT
Sarepta Therapeutics
SRPT
$1.64B
$3.86M 0.29%
+100,000
New +$3.24M
BAX icon
61
CALL
Baxter International
BAX
$12.8B
$3.81M 0.28%
+100,000
New +$3.66M
VTAE
62
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$3.62M 0.27%
200,000
– –
AKBA icon
63
Akebia Therapeutics
AKBA
$338M
$3.36M 0.25%
260,000
– –
WBA
64
DELISTED
Walgreens Boots Alliance
WBA
$3M 0.22%
35,292
– –
ELGX
65
DELISTED
Endologix Inc
ELGX
$2.97M 0.22%
30,000
+29,424
+5,108% +$3.15M
CI icon
66
Cigna
CI
$78.4B
$2.93M 0.22%
20,000
+530
+3% +$72.8K
MDCO
67
DELISTED
Medicines Co
MDCO
$2.8M 0.21%
+75,000
New +$2.83M
HEWG
68
DELISTED
iShares Currency Hedged MSCI Germany ETF
HEWG
$2.44M 0.18%
100,000
-45,000
-31% -$1.11M
TTNP
69
DELISTED
Titan Pharmaceuticals
TTNP
$2.32M 0.17%
+145
New +$2.36M
MGCD
70
DELISTED
MGC Diagnostics Corporation
MGCD
$2.21M 0.16%
336,287
– –
CPRX
71
DELISTED
Catalyst Pharmaceutical
CPRX
$2.08M 0.15%
851,200
– –
CRBP icon
72
Corbus Pharmaceuticals
CRBP
$165M
$2.06M 0.15%
41,667
– –
NEOS
73
DELISTED
Neos Therapeutics, Inc
NEOS
$2.04M 0.15%
142,603
-228,463
-62% -$3.45M
EYPT icon
74
EyePoint Inc
EYPT
$999M
$2M 0.15%
41,500
+10,000
+32% +$390K
DSCI
75
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$1.84M 0.14%
402,884
+42,300
+12% +$201K
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2015 Portfolio in Review

As of Q4 2015, Perceptive Advisors held 199 positions worth $1.35B, up 8% from $1.25B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors withdrew a net $51.8M in Q4 2015, closing 45 positions and reducing 31 holdings. Its most notable exit was RELYPSA INC COM, an estimated $18.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 78% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Perceptive Advisors opened a new position in Allergan plc worth $45.3M.

  • Perceptive Advisors's largest Q4 2015 buy was Allergan plc: 145,000 shares worth $45.3M.
  • Perceptive Advisors added most to Teva Pharmaceuticals in Q4 2015, an estimated $19.8M increase.
  • Perceptive Advisors's biggest Q4 2015 reduction was Neurocrine Biosciences, cutting an estimated $22.7M.
  • Perceptive Advisors fully exited RELYPSA INC COM in Q4 2015, selling an estimated $18.3M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $1.35B portfolio in Q4 2015.
  • Perceptive Advisors opened 40 new positions and closed 45 in Q4 2015.
  • Perceptive Advisors's portfolio value rose 8% quarter-over-quarter to $1.35B.

Based on Perceptive Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.